Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy

Brain Pathology

Volumn 20, Issue 4, 2010, Pages 845-856

  Berger, Johannes ^a   Pujol, Aurora ^b,c,d   Aubourg, Patrick ^e,f   Forss Petter, Sonja ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institut de Neuropatologia   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e INSERM   (France)

^f HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

4 phenylbutyrate; ABCD1; ABCD2; Antioxidant; Histone deacetylase inhibitor; Lorenzo's oil; Lovastatin; Therapy; Valproic acid; X ALD

Indexed keywords

4 PHENYLBUTYRIC ACID; ABC TRANSPORTER; ABC TRANSPORTER D1; ABC TRANSPORTER D2; ANTIOXIDANT; BETA1A INTERFERON; BUTYRIC ACID DERIVATIVE; COLESTIPOL; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXTRAN DERIVATIVE; DEXTRAN SULPHATE; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE ACID PROTEIN; LORENZO OIL; MEVINOLIN; MITOXANTRONE; NATALIZUMAB; PLACEBO; SIMVASTATIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VERY LONG CHAIN FATTY ACID; VORINOSTAT; DRUG COMBINATION; ERUCIC ACID; FATTY ACID; TRIOLEIN;

ABCD1 GENE; ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADRENOLEUKODYSTROPHY; CHILDHOOD ADRENOLEUKODYSTROPHY; CLINICAL TRIAL; CONFERENCE PAPER; CORTICOTROPIN BLOOD LEVEL; DIET THERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; ENCEPHALITIS; GENE; GENE TARGETING; GENE THERAPY; GONADAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEPTOR UPREGULATION; TREATMENT DURATION; TREATMENT FAILURE; X CHROMOSOME LINKED DISORDER; DRUG COMBINATION; METABOLISM;

ADRENOLEUKODYSTROPHY; DRUG COMBINATIONS; ERUCIC ACIDS; FATTY ACIDS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRIOLEIN;

EID: 77953209828     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2010.00393.x     Document Type: Conference Paper

References (113)

1. Albet S, Causeret C, Bentejac M, Mandel JL, Aubourg P, Maurice B (1997) Fenofibrate differently alters expression of genes encoding ATP-binding transporter proteins of the peroxisomal membrane. FEBS Lett 405 : 394 397.
2. Albet S, Bentejac M, Savary S, Gondcaille C, Netik A, Berger J et al (2001) Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression. Biochim Biophys Acta 1517 : 257 269.
3. Asheuer M, Bieche I, Laurendeau I, Moser A, Hainque B, Vidaud M, Aubourg P (2005) Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Hum Mol Genet 14 : 1293 1303.
4. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, Jambaqué I et al (1993) A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 329 : 745 752.
5. Bambauer R, Schiel R, Cordes H, Latza R (2000) Therapeutic plasma exchange in treatment of adrenoleukodystrophy. Ther Apher 4 : 338 341.
6. Berger J, Molzer B, Faé I, Bernheimer H (1994) X-linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem Biophys Res Commun 205 : 1638 1643.
7. Berger J, Albet S, Bentejac M, Netik A, Holzinger A, Roscher AA et al (1999) The four murine peroxisomal ABC-transporter genes differ in constitutive, inducible and developmental expression. Eur J Biochem 265 : 719 727.
8. Berger J, Gärtner J (2006) X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 1763 : 1721 1732.
9. Bezman L, Moser AB, Raymond GV, Rinaldo P, Watkins PA, Smith KD et al (2001) Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 49 : 512 517.
10. Block G, Jensen CD, Morrow JD, Holland N, Norkus EP, Milne GL et al (2008) The effect of vitamins C and E on biomarkers of oxidative stress depends on baseline level. Free Radic Biol Med 45 : 377 384.
11. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I et al (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 : 2481 2489.
12. Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S (1994) High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57 : 69 70.
13. Cartier N, Guidoux S, Rocchiccioli F, Aubourg P (2000) Simvastatin does not normalize very long chain fatty acids in adrenoleukodystrophy mice. FEBS Lett 478 : 205 208.
14. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 : 818 823.
15. Cartier N, Aubourg P (2010) Hematopoietic stem cell transplantation and gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 20 : 857 862.
16. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325 : 834 840.
17. De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370 : 737 749.
18. Dover GJ, Brusilow S, Charache S (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84 : 339 343.
19. Eichler FS, Barker PB, Cox C, Edwin D, Ulug AM, Moser HW, Raymond GV (2002) Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy. Neurology 58 : 901 907.
20. Eichler F, Mahmood A, Loes D, Bezman L, Lin D, Moser HW, Raymond GV (2007) Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy. Arch Neurol 64 : 659 664.
21. Eichler FS, Ren JQ, Cossoy M, Rietsch AM, Nagpal S, Moser AM et al (2008) Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy. Ann Neurol 63 : 729 742.
22. Engelen M, Ofman R, Dijkgraaf MG, Hijzen M, van der Wardt LA, van Geel BM et al (2010) Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 362 : 276 277.
23. Faraco G, Pitelli M, Cavone L, Fossati S, Porcu M, Mascagni P et al (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 36 : 269 279.
24. Ferrer I, Kapfhammer JP, Hindelang C, Kemp S, Troffer-Charlier N, Broccoli V et al (2005) Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 14 : 3565 3577.
25. Flavigny E, Sanhaj A, Aubourg P, Cartier N (1999) Retroviral-mediated adrenoleukodystrophy-related gene transfer corrects very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts: implications for therapy. FEBS Lett 448 : 261 264.
26. Forss-Petter S, Werner H, Berger J, Lassmann H, Molzer B, Schwab MH et al (1997) Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J Neurosci Res 50 : 829 843.
27. Fourcade S, Savary S, Albet S, Gauthé D, Gondcaille C, Pineau T et al (2001) Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. Eur J Biochem 268 : 3490 3500.
28. Fourcade S, Savary S, Gondcaille C, Berger J, Netik A, Cadepond F et al (2003) Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2). Mol Pharmacol 63 : 1296 1303.
29. Fourcade S, López-Erauskin J, Galino J, Duval C, Naudi A, Jove M et al (2008) Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet 17 : 1762 1773.
30. Fourcade S, Ruiz M, Camps C, Schlüter A, Houten SM, Mooyer PA et al (2009) A key role for the peroxisomal ABCD2 transporter in fatty acid homeostasis. Am J Physiol Endocrinol Metab 296 : E211 E221.
31. Fourcade S, Ruiz M, Guilera C, Hahnen E, Brichta L, Naudi A et al (2010) Valproic acid induces antioxidant effects in X-linked Adrenoleukodystrophy. Hum Mol Genet (in press) doi: 10.1093/hmg/ddq082.
32. Fukuchi M, Nii T, Ishimaru N, Minamino A, Hara D, Takasaki I et al (2009) Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions. Neurosci Res 65 : 35 43.
33. Genin EC, Gondcaille C, Trompier D, Savary S (2009) Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics. J Steroid Biochem Mol Biol 116 : 37 43.
34. Gilg AG, Singh AK, Singh I (2000) Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. J Neuropathol Exp Neurol 59 : 1063 1069.
35. Gondcaille C, Depreter M, Fourcade S, Lecca MR, Leclercq S, Martin PGP et al (2005) Phenylbutyrate upregulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 169 : 93 104.
36. Guimarães CP, Domingues P, Aubourg P, Fouquet F, Pujol A, Jimenez-Sanchez G et al (2004) Mouse liver PMP70 and ALDP: homomeric interactions prevail in vivo. Biochim Biophys Acta 1689 : 235 243.
37. Hahnen E, Eyüpoglu IY, Brichta L, Haastert K, Tränkle C, Siebzehnrübl FA et al (2006) In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 98 : 193 202.
38. Hahnen E, Hauke J, Tränkle C, Eyüpoglu IY, Wirth B, Blümcke I (2008) Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin Investig Drugs 17 : 1 16.
39. Halliwell B (2000) The antioxidant paradox. Lancet 355 : 1179 1180.
40. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18 : 685 716.
41. Hein S, Schönfeld P, Kahlert S, Reiser G (2008) Toxic effects of X-linked adrenoleukodystrophy-associated, very long chain fatty acids on glial cells and neurons from rat hippocampus in culture. Hum Mol Genet 17 : 1750 1761.
42. Hillebrand M, Verrier SE, Ohlenbusch A, Schäfer A, Söling HD, Wouters FS, Gärtner J (2007) Live cell FRET microscopy: homo- and heterodimerization of two human peroxisomal ABC transporters, the adrenoleukodystrophy protein (ALDP, ABCD1) and PMP70 (ABCD3). J Biol Chem 282 : 26997 27005.
43. Holzinger A, Kammerer S, Berger J, Roscher AA (1997) cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 239 : 261 264.
44. Höftberger R, Kunze M, Weinhofer I, Aboul-Enein F, Voigtländer T, Oezen I et al (2007) Distribution and cellular localization of adrenoleukodystrophy protein in human tissues: implications for X-linked adrenoleukodystrophy. Neurobiol Dis 28 : 165 174.
45. Kashiwayama Y, Seki M, Yasui A, Murasaki Y, Morita M, Yamashita Y et al (2009) 70-kDa peroxisomal membrane protein related protein (P70R/ABCD4) localizes to endoplasmic reticulum not peroxisomes, and NH2-terminal hydrophobic property determines the subcellular localization of ABC subfamily D proteins. Exp Cell Res 315 : 190 205.
46. Kazantsev AG, Thompson LM (2008) Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Rev 7 : 854 868.
47. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, Moser AB et al (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 4 : 1261 1268.
48. Khan M, Singh J, Singh I (2008) Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem 106 : 1766 1779.
49. Khurana TS, Davies KE (2003) Pharmacological strategies for muscular dystrophy. Nat Rev Drug Discov 2 : 379 390.
50. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, Casaccia P (2010) HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 13 : 180 189.
51. Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Ozcürümez M, Liebisch G et al (2000) ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A 97 : 817 822.
52. Korenke GC, Christen HJ, Kruse B, Hunneman DH, Hanefeld F (1997) Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. J Inherit Metab Dis 20 : 59 66.
53. Köhler W, Sokolowski P (2005) Clinical phenotypes, diagnosis and treatment of adulthood X-linked adrenoleukodystrophy. In : Understanding and Treating Adrenoleukodystrophy. Present State and Future Perspectives, J Berger et al (ed.), pp. 28 60. SPS Verlagsgesellschaft
54. Krysko O, Hulshagen L, Janssen A, Schütz G, Klein R, De Bruycker M et al (2007) Neocortical and cerebellar developmental abnormalities in conditions of selective elimination of peroxisomes from brain or from liver. J Neurosci Res 85 : 58 72.
55. Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G (2003) Real-time reverse transcription PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49 : 230 238.
56. Lee MH, Kim M, Lee BH, Kim JH, Kang KS, Kim HL et al (2008) Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver. Toxicol Appl Pharmacol 226 : 271 284.
57. Li X, Baumgart E, Dong G-X, Morrell JC, Jimenez-Sanchez G, Valle D et al (2002) PEX11α is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor α-mediated peroxisome proliferation. Mol Cell Biol 22 : 8226 8240.
58. Liu LX, Janvier K, Berteaux-Lecellier V, Cartier N, Benarous R, Aubourg P (1999) Homo- and heterodimerization of peroxisomal ATP-binding cassette half-transporters. J Biol Chem 274 : 32738 32743.
59. Mahmood A, Dubey P, Moser HW, Moser A (2005) X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant 9 (Suppl. 7 55 62.
60. Maier EM, Mayerhofer PU, Asheuer M, Köhler W, Rothe M, Muntau AC et al (2008) X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype. Biochem Biophys Res Commun 377 : 176 180.
61. Mastroeni R, Bensadoun JC, Charvin D, Aebischer P, Pujol A, Raoul C (2009) Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model. Ann Neurol 66 : 117 122.
62. McGovern MM, Wasserstein MP, Aron A, Perrine SP (2003) Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy. J Pediatr 142 : 709 713.
63. McGuinness MC, Zhang HP, Smith KD (2001) Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol Genet Metab 74 : 256 263.
64. McGuinness MC, Lu JF, Zhang HP, Dong GX, Heinzer AK, Watkins PA et al (2003) Role of ALDP (ABCD1) and mitochondria in X-linked adrenoleukodystrophy. Mol Cell Biol 23 : 744 753.
65. Miike T, Taku K, Tamura T, Ohta J, Ozaki M, Yamamoto C et al (1989) Clinical improvement of adrenoleukodystrophy following intravenous gammaglobulin therapy. Brain Develop 11 : 134 137.
66. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 : 38 51.
67. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J et al (1992) Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis 15 : 645 664.
68. Moser HW (2005) Adrenoleukodystrophy: historical review, clinical spectrum, and aspects of treatment; current developments and evaluation of therapies. In : Understanding and Treating Adrenoleukodystrophy. Present State and Future Perspectives, J Berger et al (ed.), pp. 28 60. SPS Verlagsgesellschaft
69. Moser HW, Loes DJ, Melhem ER, Raymond GV, Bezman L, Cox CS, Lu SE (2000) X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 31 : 227 239.
70. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB (2001) X-Linked adrenoleukodystrophy. In : The Metabolic and Molecular Bases of Inherited Disease, 8th Ed edn. CR Scriver, AL Beaudet, WS Sly, D Valle (eds), pp. 3257 3301. McGraw-Hill
71. Moser HW, Raymond GV, Lu SE, Muenz LR, Moser AB, Xu J et al (2005) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo's oil. Arch Neurol 62 : 1073 1080.
72. Moser HW, Mahmood A, Raymond GV (2007) X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3 : 140 151.
73. Mundy HR, Jones SJ, Hobart JC, Hanna MG, Lee PJ (2003) A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy. Neurology 26 : 528 530.
74. Murphy JV, Marquardt KM, Moser HW, Van Duyn MA (1982) Treatment of adrenoleukodystrophy by diet and plasmapheresis. Ann Neurol 12 : 220.
75. Naidu S, Bresnan MJ, Griffin D, O'Toole S, Moser HW (1988) Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol 45 : 846 848.
76. Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, Berger J (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum Mol Genet 8 : 907 913.
77. Pai GS, Khan M, Barbosa E, Key LL, Craver JR, Curé JK et al (2000) Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 69 : 312 322.
78. Peters C, Charnas LR, Tan Y, Ziegler RS, Shapiro EG, DeFor T et al (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104 : 881 888.
79. Pineda M, Arpa J, Montero R, Aracil A, Domínguez F, Galván M et al (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12 : 470 475.
80. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW (2000) Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 59 : 89 102.
81. Powers JM, Pei Z, Heinzer AK, Deering R, Moser AB, Moser HW et al (2005) Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 64 : 1067 1079.
82. Pujol A, Singh I (2010) Pathomechanisms of X-adrenoleukodystrophy: an hypothesis. Brain Pathol 20 : 838 844.
83. Pujol A, Troffer-Charlier N, Metzger E, Chimini G, Mandel JL (2000) Characterization of the adrenoleukodystrophy-related (ALDR, ABCD2) gene promoter: inductibility by retinoic acid and forskolin. Genomics 70 : 131 139.
84. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL (2002) Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 11 : 499 505.
85. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N et al (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 13 : 2997 3006.
86. Rampler H, Weinhofer I, Netik A, Forss-Petter S, Brown PJ, Oplinger JA et al (2003) Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. Mol Genet Metab 80 : 398 407.
87. Raymond GV, Seidman R, Monteith TS, Kolodny E, Sathe S, Mahmood A, Powers JM (2010) Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci 290 : 70 74.
88. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME et al (1989) Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 39 : 1415 1422.
89. Roberts LJ 2nd., Oates JA, Linton MF, Fazio S, Meador BP, Gross MD et al (2007) The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 43 : 1388 1393.
90. Rothstein JD (2009) Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 65 (Suppl 1 S3 S9.
91. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP Jr. (1975) Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol 32 : 577 591.
92. Schulz JB, Boesch S, Bürk K, Dürr A, Giunti P, Mariotti C et al (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 5 : 222 234.
93. Silva MFB, Aires CCP, Luis PBM, Ruiter JPN, IJlst L, Duran M et al (2007) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31 : 205 216.
94. Singh I, Pahan K, Khan M (1998) Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett 426 : 342 346.
95. Singh I, Khan M, Key L, Pai S (1998) Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 339 : 702 703.
96. Smith KD, Kemp S, Braiterman LT, Lu JF, Wei HM, Geraghty M et al (1999) X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 24 : 521 535.
97. Smith SA, Golay X, Fatemi A, Mahmood A, Raymond GV, Moser HW et al (2009) Quantitative magnetization transfer characteristics of the human cervical spinal cord in vivo: application to adrenomyeloneuropathy. Magn Reson Med 61 : 22 27.
98. Stumpf DA, Hayward A, Haas R, Frost M, Schaumburg HH (1981) Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol 38 : 48 49.
99. Swingler TE, Kevorkian L, Culley KL, Illman SA, Young DA, Parker AE et al (2010) MMP28 gene expression is regulated by Sp1 transcription factor acetylation. Biochem J (in press) doi: 10.1042/BJ20091798.
100. Tanaka AR, Tanabe K, Morita M, Kurisu M, Kasiwayama Y, Matsuo M et al (2002) ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1). J Biol Chem 277 : 40142 40147.
101. Troffer-Charlier N, Doerflinger N, Metzger E, Fouquet F, Mandel JL, Aubourg P (1998) Mirror expression of adrenoleukodystrophy and adrenoleukodystrophy related genes in mouse tissues and human cell lines. Eur J Cell Biol 75 : 254 264.
102. Unterrainer G, Molzer B, Forss-Petter S, Berger J (2000) Co-expression of mutated and normal adrenoleukodystrophy protein reduces protein function: implications for gene therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 9 : 2609 2616.
103. van Geel BM, Assies J, Haverkort EB, Koelman JH, Verbeeten B Jr., Wanders RJ, Barth PG (1999) Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J Neurol Neurosurg Psychiatry 67 : 290 299.
104. Vargas CR, Wajner M, Sirtori LR, Goulart L, Chiochetta M, Coelho D et al (2004) Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 1688 : 26 32.
105. Verrips A, Willemsen MA, Rubio-Gozalbo E, De Jong J, Smeitink JA (2000) Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy. Ann Neurol 47 : 552 553.
106. + regulatory T cells. Nat Rev Drug Discov 8 : 969 981.
107. Weinhofer I, Forss-Petter S, Zigman M, Berger J (2002) Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 11 : 2701 2708.
108. Weinhofer I, Forss-Petter S, Kunze M, Zigman M, Berger J (2005) X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism. FEBS Lett 579 : 5512 5516.
109. Weinhofer I, Kunze M, Rampler H, Bookout AL, Forss-Petter S, Berger J (2005) Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. J Biol Chem 280 : 41243 41251.
110. Weinhofer I, Kunze M, Rampler H, Forss-Petter S, Samarut J, Plateroti M, Berger J (2008) Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression. Eur J Cell Biol 87 : 933 945.
111. Weller M, Liedtke W, Petersen D, Opitz H, Poremba M (1992) Very-late-onset adrenoleukodystrophy: possible precipitation of demyelination by cerebral contusion. Neurology 42 : 367 370.
112. Yamada T, Shinnoh N, Taniwaki T, Ohyagi Y, Asahara H, Horiuchi KiraJ (2000) Lovastatin does not correct the accumulation of very long-chain fatty acids in tissues of adrenoleukodystrophy protein-deficient mice. J Inherit Metab Dis 23 : 607 614.
113. Zhou C, Huang Y, Przedborski S (2008) Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147 : 93 104.